Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Lurbinectedin, a novel agent, failed to exhibit superiority over standard chemotherapy treatment in the Phase III CORAIL trial (NCT02421588). Domenica Lorusso, MD, PhD, of the IRCCS National Cancer Institute, Milan, Italy, discusses the implications of this result at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.